Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters

Database
Language
Affiliation country
Publication year range
1.
Br J Nutr ; 120(7): 751-762, 2018 10.
Article in English | MEDLINE | ID: mdl-30105962

ABSTRACT

7-Hydroxymatairesinol (7-HMR) is a plant lignan abundant in various concentrations in plant foods. The objective of this study was to test HMRLignan™, a purified form of 7-HMR, and the corresponding Picea abies extract (total extract P. abies; TEP) as dietary supplements on a background of a high-fat diet (HFD)-induced metabolic syndrome in mice and in the 3T3-L1 adipogenesis model. Mice, 3 weeks old, were fed a HFD for 60 d. Subgroups were treated with 3 mg/kg body weight 7-HMR (HMRLignan™) or 10 mg/kg body weight TEP by oral administration. 7-HMR and TEP limited the increase in body weight (-11 and -13 %) and fat mass (-11 and -18 %) in the HFD-fed mice. Epididymal adipocytes were 19 and -12 % smaller and the liver was less steatotic (-62 and -65 %). Serum lipids decreased in TEP-treated mice (-11 % cholesterol, -23 % LDL and -15 % TAG) and sugar metabolism was ameliorated by both lignan preparations, as shown by a more than 70 % decrease in insulin secretion and insulin resistance. The expression of several metabolic genes was modulated by the HFD with an effect that was reversed by lignan. In 3T3-L1 cells, the 7-HMR metabolites enterolactone (ENL) and enterodiol (END) showed a 40 % inhibition of cell differentiation accompanied by the inhibited expression of the adipogenic genes PPARγ, C/EBPα and aP2. Furthermore, END and ENL caused a 10 % reduction in TAG uptake in HEPA 1-6 hepatoma cells. In conclusion, 7-HMR and TEP reduce metabolic imbalances typical of the metabolic syndrome and obesity in male mice, whereas their metabolites inhibit adipogenesis and lipid uptake in vitro.


Subject(s)
Blood Glucose/metabolism , Body Weight/drug effects , Diet, High-Fat , Lignans/pharmacology , Lipid Metabolism/drug effects , Metabolic Syndrome/drug therapy , Picea/chemistry , 3T3-L1 Cells , 4-Butyrolactone/analogs & derivatives , 4-Butyrolactone/pharmacology , 4-Butyrolactone/therapeutic use , Adipogenesis/drug effects , Adipogenesis/genetics , Adipose Tissue/cytology , Adipose Tissue/drug effects , Adipose Tissue/metabolism , Animals , Anti-Obesity Agents/pharmacology , Anti-Obesity Agents/therapeutic use , Dietary Supplements , Fatty Liver/drug therapy , Fatty Liver/metabolism , Gene Expression , Insulin Resistance , Lignans/therapeutic use , Lipids/blood , Male , Metabolic Syndrome/blood , Metabolic Syndrome/etiology , Metabolic Syndrome/metabolism , Mice , Mice, Inbred C57BL , Obesity/blood , Obesity/etiology , Obesity/metabolism , Obesity/prevention & control , Plant Extracts/pharmacology , Plant Extracts/therapeutic use
2.
Nat Prod Commun ; 12(1): 139-146, 2017 Jan.
Article in English | MEDLINE | ID: mdl-30549848

ABSTRACT

Cereals are suggested to be the most important sources of lignan in the diets of western populations. Recent epidemiological studies show that European subpopulations in which the major source of lignans are cereals, display lower disease frequency regarding metabolic and cardiovascular diseases. The biological mechanisms of lignan are several. Beyond their antioxidant and anti-inflammatory actions at nutritional doses some lignans regulate the activity of specific nuclear receptors (NRs), such as the estrogen receptors (ERs), and also NRs that are central switches in glucose and fatty acid metabolism such as PPARα, PPARγ and LXRs, highlighting them as selective nuclear receptor modulators (SNRMs). These include enterodiol (END) and enterolactone (ENL), the metabolites produced by the gut microbiota from food lignans. The available knowledge suggests that given some additional research it should be possible to make 'function' claims for a regular intake of lignans-rich foods related to maintaining a healthy metabolism.


Subject(s)
Biological Products/chemistry , Edible Grain/chemistry , Lignans/chemistry , Functional Food , Humans , Receptors, Cytoplasmic and Nuclear/drug effects , Receptors, Estrogen/drug effects
3.
Eur J Nutr ; 53(8): 1685-97, 2014 Dec.
Article in English | MEDLINE | ID: mdl-24566767

ABSTRACT

PURPOSE AND BACKGROUND: The focus was directed to the study of two of the most lignan-rich food sources: sesame and flaxseeds. Recent epidemiological and experimental evidences suggesting that these foods may improve metabolic functions underlying metabolic syndrome (MetS). METHODS: To characterize the effect of these oilseeds on metabolic functions, we conducted an experimental study aimed at preventing adiposity and metabolic imbalance in a mouse model of high-fat diet (HFD)-induced MetS. Statistical analysis was performed by two-way analysis of variance test followed by post hoc Bonferroni analysis. RESULTS: We studied the effect of the oilseeds sesame and flaxseed on metabolic parameters in mice on a HFD. When the HFD was integrated with 20% of sesame or flaxseed flours, the mice showed a decrease in body fat, already at day 15, from time 0. The size of the adipocytes was smaller in epididymal fat, liver steatosis was inhibited, and insulin sensitivity was higher in mice on the supplemented diets. The supplemented diets also resulted in a significant increase in the serum levels of the lignan metabolites enterodiol and enterolactone compared with the controls. The expression of genes associated with the inflammatory response, glucose metabolism, adipose metabolism and nuclear receptor were altered by the oilseed-supplemented diets. Some of the most abundant lignans in these oilseeds were studied in 3T3-L1 preadipocyte cells and were effective in inhibiting adipocyte differentiation at the minimal dose of 1 nM. CONCLUSIONS: The consumption of sesame and flaxseed may be beneficial to decrease metabolic parameters that are generally altered in MetS.


Subject(s)
Adipocytes/drug effects , Cell Differentiation/drug effects , Linseed Oil/pharmacology , Sesame Oil/pharmacology , 3T3-L1 Cells , 4-Butyrolactone/analogs & derivatives , 4-Butyrolactone/blood , Adipocytes/metabolism , Adipose Tissue/cytology , Adiposity , Animals , Diet, High-Fat , Dietary Fats/administration & dosage , Disease Models, Animal , Insulin Resistance , Lignans/blood , Male , Metabolic Syndrome/drug therapy , Mice , Mice, Inbred C57BL
4.
Blood ; 109(8): 3552-9, 2007 Apr 15.
Article in English | MEDLINE | ID: mdl-17192393

ABSTRACT

X-linked sideroblastic anemia with ataxia (XLSA/A) is caused by defects of the transporter ABCB7 and is characterized by mitochondrial iron deposition and excess of protoporphyrin in erythroid cells. We describe ABCB7 silencing in HeLa cells by performing sequential transfections with siRNAs. The phenotype of the ABCB7-deficient cells was characterized by a strong reduction in proliferation rate that was not rescued by iron supplementation, by evident signs of iron deficiency, and by a large approximately 6-fold increase of iron accumulation in the mitochondria that was poorly available to mitochondrial ferritin. The cells showed an increase of protoporphyrin IX, a higher sensitivity to H(2)O(2) toxicity, and a reduced activity of mitochondrial superoxide dismutase 2 (SOD2), while the activity of mitochondrial enzymes, such as citrate synthase or succinate dehydrogenase, and ATP content were not decreased. In contrast, aconitase activity, particularly that of the cytosolic, IRP1 form, was reduced. The results support the hypothesis that ABCB7 is involved in the transfer of iron from mitochondria to cytosol, and in the maturation of cytosolic Fe/S enzymes. In addition, the results indicate that anemia in XLSA/A is caused by the accumulation of iron in a form that is not readily usable for heme synthesis.


Subject(s)
ATP-Binding Cassette Transporters/genetics , Anemia, Iron-Deficiency/genetics , Anemia, Sideroblastic/genetics , Ataxia/genetics , Genetic Diseases, X-Linked/genetics , Iron Overload/genetics , Mitochondria/genetics , RNA Interference , ATP-Binding Cassette Transporters/antagonists & inhibitors , Anemia, Iron-Deficiency/metabolism , Anemia, Sideroblastic/metabolism , Ataxia/metabolism , Biological Transport/genetics , Cytoplasm/genetics , Cytoplasm/metabolism , Genetic Diseases, X-Linked/metabolism , HeLa Cells , Heme/biosynthesis , Heme/genetics , Humans , Iron/metabolism , Iron Overload/metabolism , Mitochondria/metabolism , Mitochondrial Proteins/genetics , Mitochondrial Proteins/metabolism , Phenotype , RNA, Small Interfering/genetics , RNA, Small Interfering/pharmacology
5.
Br J Haematol ; 127(5): 598-603, 2004 Dec.
Article in English | MEDLINE | ID: mdl-15566364

ABSTRACT

Missense mutations in the ferroportin gene (SLC11A3) result in haemochromatosis type 4 [HFE4, Online Mendelian Inheritance in Man (OMIM) reference 606069] or ferroportin disease, an autosomal dominant disorder characterized by predominantly reticuloendothelial iron accumulation. To verify whether HFE4 is caused by defective iron recycling because of loss of functionality of ferroportin, we down-regulated SLC11A gene expression in human macrophages by using small interfering RNAs (siRNAs). Transfection experiments with ferroportin siRNAs resulted in a marked reduction (about two-thirds on average) in ferroportin mRNA levels as detected by quantitative real time polymerase chain reaction. When macrophages were grown in medium supplemented with iron, cells transfected with siRNAs displayed three- to eightfold increases in staining intensities following Perls reaction. These macrophages also showed significant increases in H-ferritin content. The observation that ferroportin mRNA down-regulation to levels compatible with haplo-insufficiency causes increased iron retention and H-ferritin synthesis in cultured macrophages has important implications. First, this indicates that ferroportin levels must be finely regulated in order to maintain cellular iron homeostasis, and that both copies of SLC11A3 must function efficiently to prevent iron accumulation. Second, this observation supports the hypothesis that reticuloendothelial iron overload in patients with ferroportin disease is caused by loss-of-function mutations in the SLC11A3 gene that mainly impair macrophage iron recycling.


Subject(s)
Cation Transport Proteins/genetics , Ferritins/biosynthesis , Iron/metabolism , Macrophages/metabolism , Cation Transport Proteins/metabolism , Cells, Cultured , Gene Expression Regulation , Gene Silencing , Hemostasis , Humans , RNA, Messenger/analysis , RNA, Small Interfering/pharmacology , Reverse Transcriptase Polymerase Chain Reaction , Transfection/methods
6.
Blood ; 103(6): 2377-83, 2004 Mar 15.
Article in English | MEDLINE | ID: mdl-14615379

ABSTRACT

We describe the use of small interfering RNAs (siRNAs) to down-regulate H- and L-ferritin levels in HeLa cells. siRNAs repressed H- and L-ferritin expression to about 20% to 25% of the background level in both stable and transient transfections. HeLa cells transfected with H- and L-ferritin cDNAs were analyzed in parallel to compare the effects of ferritin up- and down-regulation. We found that large modifications of L-ferritin levels did not affect iron availability in HeLa cells but positively affected cell proliferation rate in an iron-independent manner. The transient down-regulation of H-ferritin modified cellular iron availability and resistance to oxidative damage, as expected. In contrast, the stable suppression of H-ferritin in HeLa cell clones transfected with siRNAs did not increase cellular iron availability but made cells less resistant to iron supplementation and chelation. The results indicate that L-ferritin has no direct effects on cellular iron homeostasis in HeLa cells, while it has new, iron-unrelated functions. In addition, they suggest that H-ferritin function is to act as an iron buffer.


Subject(s)
Ferric Compounds/toxicity , Ferritins/genetics , Ferritins/metabolism , Quaternary Ammonium Compounds/toxicity , Buffers , Cell Division/drug effects , Cell Division/physiology , DNA, Complementary , Down-Regulation , Gene Expression , HeLa Cells , Humans , Iron/metabolism , Oxidative Stress/physiology , RNA, Small Interfering , Transfection , Up-Regulation
SELECTION OF CITATIONS
SEARCH DETAIL